{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:52:17Z","timestamp":1790401937702,"version":"4.1.0"},"reference-count":59,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0076462","type":"journal-article","created":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T22:51:44Z","timestamp":1380667904000},"page":"e76462","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":51,"title":["Netazepide, a Gastrin Receptor Antagonist, Normalises Tumour Biomarkers and Causes Regression of Type 1 Gastric Neuroendocrine Tumours in a Nonrandomised Trial of Patients with Chronic Atrophic Gastritis"],"prefix":"10.1371","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct01339169","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Andrew R.","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Boyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islay A.","family":"Steele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Varro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Mark","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,10,1]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/j.1365-2036.2006.03130.x","article-title":"Review article: pathogenesis and management of gastric carcinoid tumours","volume":"24","author":"MD Burkitt","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"ref2","first-page":"A50year","author":"I Modlin","year":"2004"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1007\/s00464-005-0232-4","article-title":"Gastric carcinoids: a temporal increase with proton pump introduction","volume":"19","author":"N Hodgson","year":"2005","journal-title":"Surg Endosc"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1038\/ajg.2010.341","article-title":"Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971","volume":"105","author":"L Ellis","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1055\/s-0030-1255564","article-title":"Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems?","volume":"42","author":"H Scher\u00fcbl","year":"2010","journal-title":"Endoscopy"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1159\/000085237","article-title":"Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS)","volume":"80","author":"U Plockinger","year":"2004","journal-title":"Neuroendocrinol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000335600","article-title":"ENETS 2011 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: An Update","volume":"95","author":"R Salazar","year":"2012","journal-title":"Neuroendocrinol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/MPA.0b013e3181ebb168","article-title":"North American Neuroendocrine Tumor Society (NANETS). NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas","volume":"39","author":"MH Kulke","year":"2010","journal-title":"Pancreas"},{"key":"ref9","first-page":"269","article-title":"Endoscopic resection with a two-channel videoendoscope for gastric carcinoid tumors","volume":"51","author":"K Higashino","year":"2004","journal-title":"Hepatogastroenterology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/j.1440-1746.2009.05909.x","article-title":"En-bloc resection of multiple type 1 gastric carcinoid tumors by endoscopic multi-band mucosectomy","volume":"24","author":"AD Hopper","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000329043","article-title":"Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate","volume":"95","author":"E Merola","year":"2012","journal-title":"Neuroendocrinol"},{"key":"ref12","first-page":"1046","article-title":"Antrectomy for multicentric, argyrophil gastric carcinoids: a preliminary report","volume":"104","author":"FE Eckhauser","year":"1988","journal-title":"Surgery"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/0016-5085(92)90787-Y","article-title":"Rapid regression of enterochromaffinlike cell gastric carcinoids in pernicious anemia after antrectomy","volume":"102","author":"BI Hirschowitz","year":"1992","journal-title":"Gastroenterology"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/01.sla.0000167862.52309.7d","article-title":"Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type","volume":"242","author":"K Borch","year":"2005","journal-title":"Ann Surg"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/jso.20468","article-title":"Presentation, treatment, and outcome of type 1 gastric carcinoid tumors","volume":"93","author":"GF Dakin","year":"2006","journal-title":"J Surg Oncol"},{"key":"ref16","first-page":"379","article-title":"Usefulness of laparoscope-assisted antrectomy for gastric carcinoids with hypergastrinemia","volume":"57","author":"M Hoshino","year":"2010","journal-title":"Hepatogastroenterology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jss.2010.01.005","article-title":"Laparoscopic antrectomy for the treatment of type I gastric carcinoid tumors","volume":"162","author":"J Ozao-Choy","year":"2010","journal-title":"J Surg Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/00365520410005225","article-title":"Treatment of ECL cell carcinoids with octreotide LAR","volume":"39","author":"V Fykse","year":"2004","journal-title":"Scand J Gastroenterol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1440-1746.2009.06131.x","article-title":"Treatment of type I gastric neuroendocrine tumors with somatostatin analogs","volume":"25","author":"MS Khuroo","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1530\/EJE-08-0420","article-title":"Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours","volume":"159","author":"S Grozinsky-Glasberg","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1677\/ERC-07-0251","article-title":"Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs","volume":"15","author":"D Campana","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1046\/j.1365-2362.2001.00890.x","article-title":"Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy","volume":"31","author":"S Sanduleanu","year":"2001","journal-title":"Eur J Clin Invest"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1530\/eje.1.01862","article-title":"Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids","volume":"152","author":"M Peracchi","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s13277-010-0045-5","article-title":"A meal test improves the specificity of chromogranin A as a marker of neuroendocrine neoplasia","volume":"31","author":"CS Jianu","year":"2010","journal-title":"Tumour Biol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1210\/jcem-71-6-1658","article-title":"Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly","volume":"71","author":"U Pl\u00f6ckinger","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev.physiol.63.1.119","article-title":"The gastrins: their production and biological activities","volume":"63","author":"GJ Dockray","year":"2001","journal-title":"Annu Rev Physiol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1034\/j.1600-0773.2002.910602.x","article-title":"Gastrin agonists and antagonists","volume":"91","author":"JW Black","year":"2002","journal-title":"Pharmacol Toxicol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/med.10042","article-title":"Cholecystokinin antagonists: pharmacological and therapeutic potential","volume":"23","author":"R Herranz","year":"2003","journal-title":"Med Res Rev"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2174\/156802607780960519","article-title":"Role of CCK\/gastrin receptors in gastrointestinal\/metabolic diseases and results of human studies using gastrin\/CCK receptor agonists\/antagonists in these diseases","volume":"7","author":"MJ Berna","year":"2007","journal-title":"Curr Top Med Chem"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1021\/jm960669+","article-title":"(3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin\/CCK-B antagonist","volume":"31","author":"G Semple","year":"1997","journal-title":"J Med Chem"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1046\/j.1365-2036.1997.110281000.x","article-title":"YF476 is a new potent and selective gastrin\/cholecystokinin-B receptor antagonist in vitro and in vivo","volume":"11","author":"Y Takinami","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"ref32","first-page":"403","article-title":"Effects of YF476, a potent and selective gastrin\/CCK-B receptor antagonist, on gastric acid secretion in beagle dogs with gastric fistula","volume":"48","author":"Y Takemoto","year":"1998","journal-title":"Arzneim Forsch"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/sj.bjp.0703342","article-title":"Long-lasting CCK2 receptor blockade after a single subcutaneous injection of YF476 or YM022","volume":"130","author":"M Kitano","year":"2000","journal-title":"Br J Pharmacol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/carcin\/bgg156","article-title":"Spontaneous ECL cell carcinomas in cotton rats: natural course and prevention by a gastrin receptor antagonist","volume":"24","author":"TC Martinsen","year":"2003","journal-title":"Carcinogenesis"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.regpep.2010.01.009","article-title":"The CCK(2) receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development","volume":"162","author":"M Kidd","year":"2010","journal-title":"Regul Pept"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/labinvest.3700462","article-title":"Gastrin-induced apoptosis contributes to carcinogenesis in the stomach","volume":"86","author":"G Cui","year":"2006","journal-title":"Lab Invest"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1053\/j.gastro.2005.03.027","article-title":"Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer","volume":"128","author":"S Takaishi","year":"2005","journal-title":"Gastroenterology"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2036.2012.05143.x","article-title":"Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects","volume":"36","author":"M Boyce","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"ref39","article-title":"Effect of repeated doses of netazepide, a gastrin receptor antagonist, omeprazole and placebo on 24-h gastric acidity and gastrin in healthy subjects","author":"M Boyce","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"ref40","article-title":"Netazepide, a gastrin\/CCK(2) receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects","author":"M Boyce","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"ref41","article-title":"Investigator\u2019s brochure for netazepide. Trio Medicines","year":"2011"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"G446","DOI":"10.1152\/ajpgi.00527.2010","article-title":"Gastrin stimulates expression of plasminogen activator inhibitor-1 in gastric epithelial cells","volume":"301","author":"KG N\u00f8rsett","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"G431","DOI":"10.1152\/ajpgi.90283.2008","article-title":"Increased expression of the urokinase plasminogen activator system by Helicobacter pylori in gastric epithelial cells","volume":"295","author":"S Kenny","year":"2008","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"G1133","DOI":"10.1152\/ajpgi.00526.2006","article-title":"Increased gastric expression of MMP-7 in hypergastrinemia and significance for epithelial-mesenchymal signaling","volume":"292","author":"A Varro","year":"2007","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1053\/gast.2002.34162","article-title":"Identification of plasminogen activator inhibitor-2 as a gastrin-regulated gene: Role of Rho GTPase and menin","volume":"123","author":"A Varro","year":"2002","journal-title":"Gastroenterology"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000199786","article-title":"Histopathological classification of nonantral gastric endocrine growths in man","volume":"41","author":"E Solcia","year":"1988","journal-title":"Digestion"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0167-0115(80)90270-0","article-title":"Immunochemical studies on big gastrin using NH2-terminal specific antisera","volume":"1","author":"GJ Dockray","year":"1980","journal-title":"Regul Pept"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1258\/000456303322326380","article-title":"Gastrin: an analytical review","volume":"40","author":"A Varro","year":"2003","journal-title":"Ann Clin Biochem"},{"key":"ref49","first-page":"317","article-title":"Validation of a liquid chromatographic-tandem mass spectrometric method for the measurement of (R)-1-[2,3- dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl]-3-(3methylaminophenyl)urea (YF476) in human plasma","volume":"772","author":"M Redrup","year":"2002","journal-title":"J Chromatogr"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1200\/JCO.2006.10.1535","article-title":"Chromogranin A: Is it a useful marker of neuroendocrine tumors?","volume":"25","author":"D Campana","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0016-5085(98)70596-7","article-title":"Octreotide suppression test predicts beneficial outcome from antrectomy in a patient with gastric carcinoid tumour","volume":"114","author":"AD Higham","year":"1998","journal-title":"Gastroenterology"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/MEG.0b013e32835cec52","article-title":"Correlation between short-term intravenous octreotide suppression test and response to antrectomy in patients with type-1 gastric neuroendocrine tumours","volume":"25","author":"SV Murugesan","year":"2013","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1177\/0091270005276738","article-title":"Dipyridamole bioavailability in subjects with reduced gastric acidity","volume":"45","author":"H Derendorf","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2036.1993.tb00103.x","article-title":"Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity","volume":"7","author":"SG Lim","year":"1993","journal-title":"Aliment Pharmacol Ther"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1053\/j.gastro.2011.01.051","article-title":"The Zollinger-Ellison syndrome and mismeasurement of gastrin","volume":"140","author":"JF Rehfeld","year":"2011","journal-title":"Gastroenterology"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1373\/clinchem.2011.179929","article-title":"Pitfalls in diagnostic gastrin measurements","volume":"58","author":"JF Rehfeld","year":"2012","journal-title":"Clin Chem"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/apt.12090","article-title":"Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A","volume":"36","author":"R Fossmark","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"ref58","article-title":"Website. Designation EU\/3\/07\/","author":"European Commission"},{"key":"ref59","article-title":"Website. Designation 07-2432","author":"US Food"}],"updated-by":[{"DOI":"10.1371\/annotation\/4afd48b1-8dc0-47cc-9c8a-99aba7623116","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000}}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0076462","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T23:33:51Z","timestamp":1540337631000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0076462"}},"subtitle":[],"editor":[{"given":"Valli","family":"De Re","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,10,1]]},"references-count":59,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2013,10,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0076462","relation":{"correction":[{"id-type":"doi","id":"10.1371\/annotation\/4afd48b1-8dc0-47cc-9c8a-99aba7623116","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,1]]}}}